The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
Open accessAbstract
Astrocytomas are among the most common brain tumors that are usually fatal in their malignant form. They appear to progress without significant impedance from the immune system, despite the presence of intratumoral T cell infiltration. To date, this has been thought to be the result of T cell immunosuppression induced by astrocytoma-derived cytokines. Here, we propose that cell contact-mediated events also play a role, since we demonstrate the in vivo expression of Fas ligand (FasL/CD95L) by human astrocytoma and the efficient killing of Fas-bearing cells by astrocytoma lines in vitro and by tumor cells ex vivo. Functional FasL is expressed by human, mouse, and rat astrocytoma and hence may be a general feature of this nonlymphoid tumor. In the brain, astrocytoma cells can potentially deliver a death signal to Fas+ cells which include infiltrating leukocytes and, paradoxically, astrocytoma cells themselves. The expression of FasL by astrocytoma cells may extend the processes that are postulated to occur in normal brain to maintain immune privilege, since we also show FasL expression by neurons. Overall, our findings suggest that FasL-induced apoptosis by astrocytoma cells may play a significant role in both immunosuppression and the regulation of tumor growth within the central nervous system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nagata, S., & Golstein, P. (1995) · Science · doi:10.1126/science.7533326 · Cited by 3,979
Phase separation of integral membrane proteins in Triton X-114 solution.
Bordier, C. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69848-0 · Cited by 3,324
Suda, T., Takahashi, T., Golstein, P., & Nagata, S. (1993) · Cell · doi:10.1016/0092-8674(93)90326-l · Cited by 2,489
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005
The New WHO Classification of Brain Tumours
Kleihues, P., Burger, P. C., & Scheithauer, B. W. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00752.x · Cited by 1,587
Fas and Perforin Pathways as Major Mechanisms of T Cell-Mediated Cytotoxicity
Kägi, D., Vignaux, F., Ledermann, B., Bürki, K., Depraetere, V., Nagata, S., Hengartner, H., & Golstein, P. (1994) · Science · doi:10.1126/science.7518614 · Cited by 1,516
Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape
Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., et al. (1996) · Science · doi:10.1126/science.274.5291.1363 · Cited by 1,249
Self-citationA role for CD95 ligand in preventing graft rejection
Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A., & Duke, R. C. (1995) · Nature · doi:10.1038/377630a0 · Cited by 1,155
Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways
Lowin, B., Hahne, M., Mattmann, C., & Tschopp, J. (1994) · Nature · doi:10.1038/370650a0 · Cited by 1,051
Self-citationThe Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell, J., O'Sullivan, G. C., Collins, J. K., & Shanahan, F. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.3.1075 · Cited by 878
Metalloproteinase-mediated release of human Fas ligand.
Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., & Yagita, H. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1777 · Cited by 822
Immunologically Privileged Sites
Barker, C. F., & Billingham, R. E. (1978) · Advances in Immunology · doi:10.1016/s0065-2776(08)60930-x · Cited by 815
Fontana, A., Kristensen, F., Dubs, R., Gemsa, D., & Weber, E. (1982) · The Journal of Immunology · doi:10.4049/jimmunol.129.6.2413 · Cited by 752
Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view
Cserr, H. F., & Knopf, P. M. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90027-5 · Cited by 653
The JAM test A simple assay for DNA fragmentation and cell death
Matzinger, P. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90325-a · Cited by 599
Fas and FasL in the homeostatic regulation of immune responses
Lynch, D. H., Ramsdell, F., & Alderson, M. R. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80079-4 · Cited by 558
Purification and characterization of the Fas-ligand that induces apoptosis.
Suda, T., & Nagata, S. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.873 · Cited by 507
French, L. E., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Müller, C., & Tschopp, J. (1996) · The Journal of cell biology · doi:10.1083/jcb.133.2.335 · Cited by 448
Self-citationHuman Fas ligand: gene structure, chromosomal location and species specificity
Takahashi, T., Tanaka, M., Inazawa, J., Abe, T., Suda, T., & Nagata, S. (1994) · International Immunology · doi:10.1093/intimm/6.10.1567 · Cited by 434
Bodmer, S., Strommer, K., Frei, K., Siepl, C., de Tribolet, N., Heid, I., & Fontana, A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.10.3222 · Cited by 386
Self-citationNervous tissue as an immune compartment: the dialect of the immune response in the CNS
Fabry, Z., Raine, C. S., & Hart, M. N. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90247-x · Cited by 357
Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y., & Fontana, A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117462 · Cited by 345
Iwai, K., Miyawaki, T., Takizawa, T., Konno, A., Ohta, K., Yachie, A., Seki, H., & Taniguchi, N. (1994) · Blood · doi:10.1182/blood.v84.4.1201.1201 · Cited by 314
Streilein, J. W. (1995) · Science · doi:10.1126/science.270.5239.1158 · Cited by 295
Human glioblastoma cells release interleukin 6 in vivo and in vitro.
Meir, E. G. V., Sawamura, Y., Diserens, A. C., Hamou, M., & de Tribolet, N. (1990) · PubMed · Cited by 235
Sarmiento, M., Dialynas, D. P., Lancki, D. W., Wall, K. A., Lorber, M. I., Loken, M. R., & Fitch, F. W. (1982) · Immunological Reviews · doi:10.1111/j.1600-065x.1982.tb01063.x · Cited by 210
Activated B cells express functional Fas ligand
Hahne, M., Renno, T., Schroeter, M., Irmler, M., French, L., Bornand, T., MacDonald, H. R., & Tschopp, J. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260332 · Cited by 201
Self-citationImmunohistological study of mononuclear cell infiltrate in malignant gliomas
Rossi, M. L., Hughes, J. T., Esiri, M. M., Coakham, H. B., & Brownell, D. B. (1987) · Acta Neuropathologica · doi:10.1007/bf00688191 · Cited by 190
Smyth, M. J., Strobl, S. L., Young, H. A., Ortaldo, J. R., & Ochoa, A. C. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.10.3289 · Cited by 160
Fabry, Z., Topham, D. J., Fee, D. B., Herlein, J. A., Carlino, J. A., Hart, M. N., & Sriram, S. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.1.325 · Cited by 95
Characterization of the non-functional Fas ligand of gld mice
Hahne, M., Peitsch, M. C., Irmler, M., Schröter, M., Lowln, B., Rousseau, M., Bron, C., Renno, T., French, L. E., & Tschopp, J. (1995) · International Immunology · doi:10.1093/intimm/7.9.1381 · Cited by 67
Self-citationImmunologically Privileged Sites
BARKER, C., & Billingham, R. E. (1978) · Advances in heterocyclic chemistry · doi:10.1016/s0065-2725(08)60012-4 · Cited by 43
Cited by
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
Brat, D. J., Bellail, A. C., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001061 · Cited by 760
Self-citationImmune escape of tumors: apoptosis resistance and tumor counterattack
Igney, F. H., & Krammer, P. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.6.907 · Cited by 468
Hesselgesser, J., Taub, D., Baskar, P., Greenberg, M., Hoxie, J., Kolson, D. L., & Horuk, R. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70230-1 · Cited by 408
Metadata
- Authors
- Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V, Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J., & Dietrich, P. Y.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-03-15
- Volume
- 99
- Issue
- 6
- Pages
- 1173-1178
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2005770035
- Cited by
- 398
- References
- 32
- FWCI
- 36.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.